Spectrum of Apolipoprotein AI and Apolipoprotein AII Proteoforms and Their Associations With Indices of Cardiometabolic Health: The CARDIA Study.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
07 09 2021
Historique:
pubmed: 3 9 2021
medline: 6 1 2022
entrez: 2 9 2021
Statut: ppublish

Résumé

Background ApoAI (apolipoproteins AI) and apoAII (apolipoprotein AII) are structural and functional proteins of high-density lipoproteins (HDL) which undergo post-translational modifications at specific residues, creating distinct proteoforms. While specific post-translational modifications have been reported to alter apolipoprotein function, the full spectrum of apoAI and apoAII proteoforms and their associations with cardiometabolic phenotype remains unknown. Herein, we comprehensively characterize apoAI and apoAII proteoforms detectable in serum and their post-translational modifications and quantify their associations with cardiometabolic health indices. Methods and Results Using top-down proteomics (mass-spectrometric analysis of intact proteins), we analyzed paired serum samples from 150 CARDIA (Coronary Artery Risk Development in Young Adults) study participants from year 20 and 25 exams. Measuring 15 apoAI and 9 apoAII proteoforms, 6 of which carried novel post-translational modifications, we quantified associations between percent proteoform abundance and key cardiometabolic indices. Canonical (unmodified) apoAI had inverse associations with HDL cholesterol and HDL-cholesterol efflux, and positive associations with obesity indices (body mass index, waist circumference), and triglycerides, whereas glycated apoAI showed positive associations with serum glucose and diabetes mellitus. Fatty-acid‒modified ApoAI proteoforms had positive associations with HDL cholesterol and efflux, and inverse associations with obesity indices and triglycerides. Truncated and dimerized proteoforms of apoAII were associated with HDL cholesterol (positively) and obesity indices (inversely). Several proteoforms had no significant associations with phenotype. Conclusions Associations between apoAI and AII and cardiometabolic indices are proteoform-specific. These results provide "proof-of-concept" that precise chemical characterization of human apolipoproteins will yield improved insights into the complex pathways through which proteins signify and mediate health and disease.

Identifiants

pubmed: 34472376
doi: 10.1161/JAHA.120.019890
pmc: PMC8649248
doi:

Substances chimiques

APOA1 protein, human 0
APOA2 protein, human 0
Apolipoprotein A-I 0
Apolipoprotein A-II 0
Cholesterol, HDL 0
Triglycerides 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e019890

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL133601
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800004I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800005I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800007I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800006I
Pays : United States
Organisme : NIGMS NIH HHS
ID : P41 GM108569
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM105538
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800003I
Pays : United States

Références

Rapid Commun Mass Spectrom. 2012 Aug 15;26(15):1711-7
pubmed: 22730091
Curr Opin Lipidol. 2019 Feb;30(1):24-29
pubmed: 30531230
J Biol Chem. 2005 Feb 18;280(7):5983-93
pubmed: 15574409
Methods Mol Biol. 2012;909:141-50
pubmed: 22903714
J Biol Chem. 2008 Apr 25;283(17):11633-44
pubmed: 18160395
J Proteome Res. 2018 Jun 1;17(6):2156-2164
pubmed: 29649363
Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801
pubmed: 20075420
J Proteomics. 2014 Jun 25;106:61-73
pubmed: 24747125
Atherosclerosis. 2020 Apr;299:56-63
pubmed: 32113648
J Am Coll Cardiol. 2016 Jan 19;67(2):193-201
pubmed: 26791067
J Lipid Res. 2015 May;56(5):972-85
pubmed: 25652088
J Clin Lipidol. 2017 Mar - Apr;11(2):362-368
pubmed: 28502492
J Lipid Res. 2017 Jul;58(7):1374-1385
pubmed: 28476857
Methods Mol Biol. 2017;1558:381-394
pubmed: 28150248
J Biol Chem. 2007 Aug 3;282(31):22249-53
pubmed: 17526499
Diabetes. 1985 May;34(5):452-61
pubmed: 3921419
Nat Struct Mol Biol. 2017 Dec;24(12):1093-1099
pubmed: 29131142
Atherosclerosis. 2008 Aug;199(2):333-9
pubmed: 18179799
J Clin Invest. 1976 Jun;57(6):1652-9
pubmed: 932199
Lancet. 2008 Jul 19;372(9634):224-33
pubmed: 18640459
Int J Mol Sci. 2019 Mar 20;20(6):
pubmed: 30897703
J Clin Lipidol. 2009 Feb;3(1):39-44
pubmed: 21291787
Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):156-63
pubmed: 19778948
FEBS Lett. 2016 Dec;590(23):4171-4179
pubmed: 27790714
J Biol Chem. 2001 Nov 16;276(46):42965-70
pubmed: 11557764
Anal Chem. 2013 Mar 5;85(5):2867-74
pubmed: 23368640
Lancet Diabetes Endocrinol. 2015 Jul;3(7):507-13
pubmed: 26025389
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7728-33
pubmed: 20388904
Diabete Metab. 1995 Apr;21(2):95-8
pubmed: 7621978
N Engl J Med. 2014 Dec 18;371(25):2383-93
pubmed: 25404125
Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12176-81
pubmed: 18719128
J Biol Chem. 1986 Mar 25;261(9):3911-4
pubmed: 3005308
Nat Med. 2014 Feb;20(2):193-203
pubmed: 24464187
PLoS Genet. 2012;8(11):e1003063
pubmed: 23209431
Onco Targets Ther. 2018 Apr 13;11:2169-2176
pubmed: 29713185
Lancet. 2012 Aug 11;380(9841):572-80
pubmed: 22607825
Anal Chem. 2014 May 20;86(10):4961-8
pubmed: 24807621
Int J Cancer. 2019 Apr 15;144(8):1877-1887
pubmed: 30259989
Nat Methods. 2013 Mar;10(3):186-7
pubmed: 23443629
J Clin Epidemiol. 1988;41(11):1105-16
pubmed: 3204420
J Clin Lipidol. 2013 Sep-Oct;7(5):484-525
pubmed: 24079290

Auteurs

John T Wilkins (JT)

Department of Medicine (Cardiology) and Department of Preventive Medicine Northwestern University Chicago IL.

Henrique S Seckler (HS)

Department of Chemistry Chemistry of Life Processes Institute and Proteomics Center of Excellence Northwestern University Evanston IL.

Jonathan Rink (J)

Department of Medicine (Urology) Northwestern University Chicago IL.

Philip D Compton (PD)

Department of Chemistry Chemistry of Life Processes Institute and Proteomics Center of Excellence Northwestern University Evanston IL.

Luca Fornelli (L)

Department of Molecular Biology University of Oklahoma Norman OK.

C Shad Thaxton (CS)

Department of Medicine (Urology) Northwestern University Chicago IL.

Rich LeDuc (R)

Department of Chemistry Chemistry of Life Processes Institute and Proteomics Center of Excellence Northwestern University Evanston IL.

David Jacobs (D)

Division of Epidemiology and Community Health School of Public Health University of Minnesota Minneapolis MN.

Peter F Doubleday (PF)

Department of Chemistry Chemistry of Life Processes Institute and Proteomics Center of Excellence Northwestern University Evanston IL.

Allan Sniderman (A)

Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention Department of Medicine McGill University Health Centre Montreal Quebec Canada.

Donald M Lloyd-Jones (DM)

Department of Medicine (Cardiology) and Department of Preventive Medicine Northwestern University Chicago IL.

Neil L Kelleher (NL)

Department of Chemistry Chemistry of Life Processes Institute and Proteomics Center of Excellence Northwestern University Evanston IL.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH